Oramed Pharmaceuticals is shifting from drug development to strategic investments, showing strong returns from stakes in Lifeward, Scilex, and Alpha Tau Medical. Alpha Tau's product has regulatory approvals and a lucrative U.S. deal but carries clinical risks. Oramed's cash is limited to $15.24M with a 12-month runway, raising concerns about potential dilution if new deals or asset sales don't occur. Investors should watch the company's ability to manage cash and capitalize on its diversified portfolio moving forward.
Argus Research increased its price target for NetApp to $225, citing a 13.5% potential upside from the current price of $198.18. NetApp reported strong fiscal Q1 2027 results with revenues up 29.9% to over $2 billion and non-GAAP EPS rising 66.5% to ...
New Jersey American Water received approval for rate increases that will add $68 million annually to its revenue. This funding supports over $1.4 billion in critical infrastructure upgrades, including replacing aging water mains and improving treatme...
abrdn U.S. Closed-End Funds announced dividend payments on September 30, 2026, for shareholders recorded by September 22, 2026. The distributions vary by fund, with amounts ranging from $0.02 to $0.26 per share. The abrdn Global Infrastructure Income...
abrdn Global Premier Properties Fund announced a new managed distribution policy to pay monthly distributions at an annualized rate of 12% of the Fund's average net asset value (NAV) per share. The first distribution under this policy is $0.12 per sh...
Coca-Cola reported strong Q2 2026 results with 5% volume growth and raised its full-year guidance, signaling robust performance driven by popular products like Coca-Cola Zero Sugar and global campaigns. In contrast, PepsiCo faced challenges, particul...
